Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3396-3401

  Sehn, Laurie H ^a   MacDonald, David ^a   Rubin, Sheldon ^a   Cantin, Guy ^a   Rubinger, Morel ^a   Lemieux, Bernard ^a   Basi, Sanraj ^a   Imrie, Kevin ^a   Gascoyne, Randy D ^a   Sussman, Jonathan ^a   Chen, Bingshu E ^a   Djurfeldt, Marina ^a   Shepherd, Lois ^a   Couban, Stephen ^a   Crump, Michael ^a  

^a Queen's Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HIGH RISK POPULATION; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; NEUROTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CANADA; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PREDNISONE; PYRAZINES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 80052739391     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.6594     Document Type: Article

References (34)

1. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
2. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
3. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
4. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
5. Belch A, Kouroukis CT, Crump M, et al: A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND 150. Ann Oncol 18:116-121, 2007 (Pubitemid 46152510)
6. Di Bella N, Taetle R, Kolibaba K, et al: Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 115:475-480, 2010
7. Fisher RI, Bernstein SH, Kahl BS, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867-4874, 2006 (Pubitemid 46655613)
8. Gerecitano J, Portlock C, Moskowitz C, et al: Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146:652-655, 2009
9. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005 (Pubitemid 46224166)
10. O'Connor OA, Portlock C, Moskowitz C, et al: Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 16:719-726, 2010
11. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005 (Pubitemid 46237441)
12. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105-2112, 2006 (Pubitemid 46622122)
13. Coiffier B, Osmanov EA, Hong X, et al: A phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab-naive or -sensitive, follicular lymphoma. Blood 116, 2010 (abstr 857)
14. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001 (Pubitemid 32691956)
15. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003 (Pubitemid 36302084)
16. Argyriou AA, Iconomou G, Kalofonos HP: Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 112:1593-1599, 2008
17. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006 (Pubitemid 46638949)
18. Furman RR, Martin P, Ruan J, et al: Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 116:5432-5439, 2010
19. Lee J, Suh C, Kang HJ, et al: Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 19:2079-2083, 2008
20. Ribrag V, Gisselbrecht C, Haioun C, et al: Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 115:4540-4546, 2009
21. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690-697, 2011
22. De Vos S, Goy A, Dakhil SR, et al: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 27:5023-5030, 2009
23. World Health Organization: Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2008
24. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993 (Pubitemid 23071057)
25. Eremenco S, Webster K, Kutikova L, et al: Development and multilingual validation of the FACT-Lymphoma instrument. Qual Life Res 13:1501, 2004
26. Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-748, 2003 (Pubitemid 38235217)
27. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
28. Bryant J, Day R: Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372-1383, 1995 (Pubitemid 26030182)
29. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
30. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999 (Pubitemid 29269108)
31. Hideshima T, Mitsiades C, Akiyama M, et al: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534, 2003 (Pubitemid 36182530)
32. O'Connor OA, Czuczman MS: Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leuk Lymphoma 49:59-66, 2008 (suppl 1)
33. Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, et al: Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 116:5605-5614, 2010
34. Rummel M, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114, 2009 (abstr 405a)